Skip to main content

Table 1 Correlations between AUF1 expression and clinicopathological characteristics in breast cancer patients

From: High AUF1 level in stromal fibroblasts promotes carcinogenesis and chemoresistance and predicts unfavorable prognosis among locally advanced breast cancer patients

Parameter Total (n = 338) AUF1 in stromal fibroblasts P value
(%) < 10 > 10
Age     
 < 50 years 247 (73.08) 182 (53.85) 65 (19.23) 0.5442
 > 50 years 91 (26.92) 70 (20.71) 21 (6.21)  
Tumor size     
 T2 78 (23.93) 57 (15.48) 21 (6.44)  
 T3 116 (35.58) 90 (27.61) 26 (7.98) 0.5799
 T4 132 (40.49) 95 (29.14) 37 (11.35)  
Stage     
 II B 85 (26.07) 62 (19.02) 23 (7.06) 0.6988
 III A 100 (30.67) 77 (23.62) 23 (7.06)  
 III B 141 (43.25) 102 (31.29) 39 (11.96)  
Ki-67 index 335    
 0 313 (93.43) 232 (69.25) 81 (24.18) 0.5924
 < 15 3 (0.90) 3 (0.90) 0 (0)  
 > 15 19 (5.76) 14 (4.18) 5 (1.49)  
Recurrence     
 No 201 (59.47) 153 (45.27) 48 (14.20) 0.4242
 Yes 137 (40.53) 99 (29.29) 38 (11.24)  
Grade     
 Gl/well diff 5 (1.48) 5 (1.48) 0 (0)  
 G2/moderately diff 169 (50.00) 134 (39.64) 35 (10.36) 0.0021
 G3/poorly diff 144 (42.60) 94 (27.81) 50 (14.79)  
 Gx/unknown 20 (5.92) 19 (5.62) 1 (0.30)  
Lymph nodes     
 N0 36 (10.65) 28 (8.28) 8 (2.37) 0.5782
 N1 182 (53.85) 139 (41.12) 43 (12.72)  
N2 87 (25.74) 60 (17.75) 27 (7.99)  
N3 33 (9.76) 25 (7.40) 8 (2.37)  
Progression     
 No 223 (65.98) 170 (50.30) 53 (15.68) 0.3243
 Yes 115 (34.02) 82 (24.26) 33 (9.76)  
Survival status     
 Alive 265 (78.40) 203 (60.06) 62 (18.34) 0.0096
 Dead 73 (21.60) 49 (14.50) 24 (7.10)  
Duration of clinical follow-up   7.8215 6.0165  
Parameter Total (n = 337) AUF1 in cancer cells P value
(%) < 10% > 10%
Age     
 < 50 years 246 (73.00) 145 (43.03) 101 (29.97) 0.0550
 > 50 years 91 (27.00) 43 (12.76) 48 (14.24)  
Tumor size     
 T2 78 (23.93) 40 (12.27) 38 (11.66)  
 T3 116 (35.58) 67 (20.55) 49 (15.03) 0.6731
 T4 132 (40.49) 73 (22.39) 132 (40.49)  
Recurrence     
 No 200 (59.35) 108 (32.05) 92 (27.30) 0.4250
 Yes 137 (40.65) 80 (23.74) 57 (16.91)  
Grade     
 G1/well diff 5 (1.48) 4(1.19) 1 (0.30)  
 G2/moderately diff 169 (50.15) 98 (29.08) 71 (21.07) 0.0295
 G3/poorly diff 143 (42.43) 70 (20.77) 73 (21.66)  
 Gx/unknown 20 (5.93) 16 (4.75) 4 (1.19)  
Stage     
 II B 85 (26.15) 46 (14.15) 39 (12.00) 0.9205
 III A 99 (30.46) 53 (16.31) 46 (14.15)  
 III B 141 (43.38) 79 (24.31) 62 (19.08)  
Lymph nodes     
 N0 36 (10.68) 14 (5.04) 19 (5.64)  
 N1 182 (54.01) 107 (31.75) 75 (22.26) 0.2923
 N2 86 (25.52) 43 (12.76) 43 (12.76)  
 N3 33 (9.79) 21 (6.23) 12 (3.56)  
Progression     
 No 222 (65.88) 116 (34.42) 106 (31.45) 0.0695
 Yes 115 (34.12) 72 (21.36) 43 (12.76)  
Survival status     
 Alive 264 (78.34) 145 (43.03) 119 (35.31) 0.5445
 Dead 73 (21.66) 43 (12.76) 30 (8.90)  
Duration of clinical follow-up   8.0190 6.5356